Biotechnology · Nasdaq
INCYIncyte Corp
- Last close
- $120.97 -0.6%
- 52-week range
- $89.25 to $132.60
- Market cap
- $24.7B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own 10 years
Below its 10-year median on 1 of 3 multiples
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- 64.2x
- Earnings yield
- 1.6%
- Price / sales
- 4.1x
- Price / book
- 4.4x
- Price / operating cash flow
- 33.1x
- EV / EBITDA
- 29.5x
- EV / sales
- 3.6x
- Free cash flow yield
- n/aNot reported
Profitability
- Gross margin
- 92.7%
- Operating margin
- 10.4%
- Net margin
- 6.7%
- Return on equity
- 7.1%
- Return on capital
- 5.6%
Growth per year
- Revenue, 3 years
- +14.8%
- Revenue, 5 years
- +14.0%
- Revenue, 9 years
- +18.6%
- EPS, 3 years
- +61.6%
Balance sheet
- Cash and investments
- $3.28B
- Total debt
- n/a
- Net cash
- $3.28B
- Debt / equity
- n/a
- Current ratio
- 3.84x
n/a: No debt reported
Shares and dividend
- Shares outstanding
- 204M
- Share count, 5 years
- -8.0%
- Beta, 1 year
- 0.47
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
JAKAFI went from 71% to 60% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| JAKAFI | $3.09B | 60.2% | +11% |
| OPZELURA | $678M | 13.2% | +33% |
| JAKAVI Royalty Revenues | $458M | 8.9% | +9% |
| NIKTIMVO | $152M | 2.9% | n/a |
| Milestone and Contract Revenues | $150M | 2.9% | +249% |
| Olumiant Royalty | $145M | 2.8% | +7% |
| Other | $432M | 8.4% | +36% |
Biotechnology peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $619B | +33% | 17.8% | 689x | 93.6x | Not enough history |
| ABBV AbbVie Inc. | $521B | +11% | 32.2% | 50.8x | 7.9x | 72nd percentile |
| AMGN Amgen Inc | $252B | +8% | 32.4% | 27.0x | 6.5x | 78th percentile |
| GILD Gilead Sciences, Inc. | $208B | +7% | -7.6% | No earnings | 6.7x | No earnings |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137B | +10% | 33.2% | 34.7x | 10.5x | 71st percentile |
| INCY Incyte Corp | $24.7B | +25% | 10.4% | 64.2x | 4.1x | 72nd percentile |
The company
- Sector
- Health Care
- Industry
- Biotechnology
- Founded
- 2001
- Headquarters
- Wilmington, DE
- Fiscal year ends
- December
- Website
- incyte.com
What it does
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about INCY.